Relmada Therapeutics
New York
About Relmada Therapeutics
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.()
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $566.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2026)
- Ticker: nasdaq:RLMD
- Website: relmada.com
- Phone: 646-876-3459
Industries & Categories
Biotechnology, Clinical Trials, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/relmada-therapeutics-25040 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.